| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
1,3-Dipalmitin is a lipid excipient used in pharmaceutical formulations, particularly Solid Lipid Nanoparticles (SLNs) and Lipid Drug Conjugates (LDCs). It does not have a specific biological target but serves as a structural lipid. It is a cerebroside found in Typhonium giganteum Engl.
|
|---|---|
| ln Vitro |
In vitro, 1,3-Dipalmitin is used as a lipid excipient in drug delivery systems. It forms solid lipid nanoparticles that can encapsulate hydrophobic drugs. It has low cytotoxicity and is biocompatible. It may also be used in studies of lipid metabolism and digestion.
|
| ln Vivo |
In vivo, 1,3-Dipalmitin is used as a component of lipid-based drug delivery systems. It is a naturally occurring lipid found in cell membranes. It is metabolized by lipases to release palmitic acid and glycerol. It is considered biocompatible and biodegradable.
|
| Enzyme Assay |
Cell-free assays for 1,3-Dipalmitin: lipid nanoparticle characterization includes particle size measurement by dynamic light scattering, zeta potential analysis, and drug encapsulation efficiency by HPLC. Lipase-mediated hydrolysis is measured by monitoring free fatty acid release using colorimetric assays. The lipid's physicochemical properties are characterized by DSC and X-ray diffraction.
|
| Cell Assay |
Cellular assays for 1,3-Dipalmitin: cells are treated with 1,3-Dipalmitin-containing nanoparticles or free lipid at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Cellular uptake of nanoparticles is assessed by fluorescence microscopy or flow cytometry. Cytotoxicity and inflammatory responses are evaluated.
|
| Animal Protocol |
In vivo animal studies for 1,3-Dipalmitin: pharmacokinetic and biodistribution studies of 1,3-Dipalmitin-based nanoparticles are performed in rodents. Animals are administered the formulation intravenously or orally. Drug concentrations in plasma and tissues are measured by HPLC or LC-MS/MS. Toxicity and tolerability are assessed by monitoring body weight, organ histology, and blood biochemistry.
|
| Toxicity/Toxicokinetics |
Toxicity of 1,3-Dipalmitin: as a lipid excipient, it has low toxicity and is considered safe for pharmaceutical use. It is biocompatible and biodegradable. High doses may cause gastrointestinal effects due to lipid digestion. It is for research use and is also used in pharmaceutical formulations.
|
| References | |
| Additional Infomation |
1,3-Dipalmitoylglycerol is a 1,3-diglyceride obtained by acylation of glycerol at the 1 and 3 positions with hexadecanoic acid (palmitic acid). It is a 1,3-diglyceride and also a hexadecanoylglycerol. Its function is related to hexadecanoic acid. 1,3-Dipalmitoylglycerol has been reported to be found in wheat (Triticum aestivum), whorled pine (Sciadopitys verticillata), and monitor lizard (Sauromatum giganteum), with relevant data available. 1,3-Dipalmitoylglycerol is a metabolite found or produced in Saccharomyces cerevisiae.
1,3-Dipalmitin is a lipid excipient used in pharmaceutical research, particularly in the development of solid lipid nanoparticles and lipid drug conjugates. It is a naturally occurring compound found in various organisms. Its primary application is in drug delivery systems. It is not a therapeutic agent and has no direct pharmacological effects. |
| Molecular Formula |
C35H68O5
|
|---|---|
| Molecular Weight |
568.91
|
| Exact Mass |
568.507
|
| CAS # |
502-52-3
|
| PubChem CID |
68149
|
| Appearance |
White to off-white solid powder
|
| Density |
0.93 g/cm3
|
| Boiling Point |
628.6ºC at 760 mmHg
|
| Melting Point |
72-74ºC
|
| Flash Point |
177.7ºC
|
| LogP |
10.396
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
40
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)O
|
| InChi Key |
GFAZGHREJPXDMH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C35H68O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(37)39-31-33(36)32-40-35(38)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33,36H,3-32H2,1-2H3
|
| Chemical Name |
(3-hexadecanoyloxy-2-hydroxypropyl) hexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7577 mL | 8.7887 mL | 17.5775 mL | |
| 5 mM | 0.3515 mL | 1.7577 mL | 3.5155 mL | |
| 10 mM | 0.1758 mL | 0.8789 mL | 1.7577 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
